The Cooper Companies, Inc. COO Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Coopersurgical Segment | $358M+7.6% | $329M+3.3% | $355.4M+3.9% | $341.9M+4.5% | $332.7M+8.5% | |
| Coopervision Segment | $723.5M+8.0% | $695.1M+7.6% | $709.7M+4.9% | $718.4M+6.3% | $669.6M+5.3% | |
| Total Assets by Business | ||||||
| CooperSurgical | $4.62B-3.1% | $4.58B-4.1% | $4.62B-4.4% | $4.67B-1.0% | $4.76B+1.5% | |
| CooperVision | $7.63B+2.2% | $7.66B+5.5% | $7.6B+4.4% | $7.51B+4.7% | $7.46B+4.9% | |
| Operating Income (Loss) by Business | ||||||
| CooperSurgical | -$225M-1,049% | $26.8M+32.7% | $3.7M-88.2% | -$4.2M-110% | $23.7M+9.7% | |
| CooperVision | $215.6M+15.7% | $210.2M+14.3% | $156.7M-16.9% | $202.6M+17.3% | $186.4M+16.4% | |
| Cost of Sales by Business | ||||||
| CooperSurgical | $116.7M+8.5% | $108.1M+8.6% | —— | —— | $107.6M+10.8% | |
| CooperVision | $229.4M+6.4% | $220.8M+7.7% | —— | —— | $215.6M-5.4% | |
| Selling, general and administrative expense by Business | ||||||
| CooperSurgical | $402.4M+194% | $128.4M-5.5% | —— | —— | $136.8M+2.4% | |
| CooperVision | $252.2M+6.5% | $237.6M+3.3% | —— | —— | $236.9M+4.1% | |
| Research and development expense by Business | ||||||
| CooperSurgical | $20.4M+2.5% | $21.9M+20.3% | —— | —— | $19.9M+10.2% | |
| CooperVision | $22.1M-13.7% | $22.4M-0.4% | —— | —— | $25.6M+23.5% | |
| Amortization of intangibles by Business | ||||||
| CooperSurgical | $43.5M-2.7% | $43.8M-2.2% | —— | —— | $44.7M+3.4% | |
| CooperVision | $4.2M-17.6% | $4.1M-14.6% | —— | —— | $5.1M-27.7% | |
| Depreciation expense by Business | ||||||
| CooperSurgical | $6.5M+10.2% | $6.5M+6.6% | —— | —— | $5.9M+6.8% | |
| CooperVision | $41.3M+11.3% | $41.1M+16.4% | —— | —— | $37.1M-2.2% | |
| CapEx by Business | ||||||
| CooperSurgical | $9.8M+12.6% | $8M-42.0% | —— | —— | $8.7M+6.7% | |
| CooperVision | $76.6M+10.4% | $94.2M+24.6% | —— | —— | $69.4M-28.6% | |
| Net Sales by Product | ||||||
| Fertility | $143.8M+13.3% | $126.6M+5.8% | $140.9M+1.2% | $137.1M+6.0% | $126.9M+2.5% | |
| Office and surgical | $214.2M+4.1% | $202.4M+1.8% | $214.5M+5.8% | $204.8M+3.5% | $205.8M+12.5% | |
| Sphere, other | $358.6M+5.1% | $343.9M+5.3% | $365M+3.3% | $359.6M+3.0% | $341.2M+4.8% | |
| Toric and multifocal | $364.9M+11.1% | $351.2M+10.0% | $344.7M+6.7% | $358.8M+9.9% | $328.4M+5.8% | |
| Net Sales by Geography | ||||||
| Europe | $341.6M+17.0% | $326.4M+13.5% | $1.46B+6.2% | $343.1M+15.5% | $291.9M+5.5% | |
| Rest of world | $192.1M-1.6% | $183.8M+1.7% | —— | $201M+3.3% | $195.2M+4.4% | |
| United States | $547.8M+6.3% | $513.9M+3.5% | $526.2M+4.1% | $516.2M+1.0% | $515.2M+7.6% | |
| Total by Geography | ||||||
| Europe | $445.7M+7.9% | $449M+14.7% | $429.1M+6.8% | $423.3M+12.0% | $413.2M— | |
| Rest of world | $257.4M-3.7% | $261.7M-2.9% | $263.5M-3.4% | $263.9M-4.2% | $267.2M— | |
| United States | $1.43B+14.5% | $1.41B+16.8% | $1.39B+16.9% | $1.3B+19.0% | $1.25B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Cooper Companies, Inc. break its business down?
- The Cooper Companies, Inc. (COO) reports net sales by business across 2 parts — Coopersurgical Segment and Coopervision Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does The Cooper Companies, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Cooper Companies, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
